Antitumor Effect of Apcin on Endometrial Carcinoma via p21-Mediated Cell Cycle Arrest and Apoptosis

Abstract

Objective

Endometrial carcinoma (EC) is a prevalent gynecological malignancy characterized by increasing incidence and mortality rates. This underscores the critical need for novel therapeutic targets. One such potential target is cell division cycle 20 (CDC20), which has been implicated in oncogenesis. This study investigated the effect of the CDC20 inhibitor Apcin on EC and elucidated the underlying mechanism involved.

Methods

The effects of Apcin on EC cell proliferation, apoptosis, and the cell cycle were evaluated using CCK8 assays and flow cytometry. RNA sequencing (RNA-seq) was subsequently conducted to explore the underlying molecular mechanism, and Western blotting and coimmunoprecipitation were subsequently performed to validate the results. Animal studies were performed to evaluate the antitumor effects in vivo. Bioinformatics analysis was also conducted to identify CDC20 as a potential therapeutic target in EC.

Results

Treatment with Apcin inhibited proliferation and induced apoptosis in EC cells, resulting in cell cycle arrest. Pathways associated with apoptosis and the cell cycle were activated following treatment with Apcin. Notably, Apcin treatment led to the upregulation of the cell cycle regulator p21, which was verified to interact with CDC20 and consequently decrease the expression of downstream cyclins in EC cells. In vivo experiments confirmed that Apcin treatment significantly impeded tumor growth. Higher CDC20 expression was observed in EC tissue than in nonmalignant tissue, and increased CDC20 expression in EC patients was associated with shorter overall survival and progress free interval.

Conclusion

CDC20 is a novel molecular target in EC, and Apcin could be developed as a candidate antitumor drug for EC treatment.

References

[1] SungH, FerlayJ, SiegelRL, et al.. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021, 71(3): 209-249

[2] BrayF, FerlayJ, SoerjomataramI, et al.. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424

[3] DouY, KawalerEA, Cui ZhouD, et al.. Proteogenomic Characterization of Endometrial Carcinoma. Cell, 2020, 180(4): 729-748.e26

[4] SiegelRL, MillerKD, FuchsHE, et al.. Cancer Statistics, 2021. CA Cancer J Clin, 2021, 71(1): 7-33

[5] SuskiJM, BraunM, StrmiskaV, et al.. Targeting cell-cycle machinery in cancer. Cancer Cell, 2021, 39(6): 759-778

[6] MalumbresM, BarbacidM. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer, 2009, 9(3): 153-166

[7] EggersmannTK, DegenhardtT, GluzO, et al.. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib. Biodrugs, 2019, 33(2): 125-135

[8] HuangP, LeX, HuangF, et al.. Discovery of a Dual Tubulin Polymerization and Cell Division Cycle 20 Homolog Inhibitor via Structural Modification on Apcin. J Med Chem, 2020, 63(9): 4685-4700

[9] RichesonKV, BodrugT, SacktonKL, et al.. Paradoxical mitotic exit induced by a small molecule inhibitor of APC/C(Cdc20). Nat Chem Biol, 2020, 16(5): 546-555

[10] SacktonKL, DimovaN, ZengX, et al.. Synergistic blockade of mitotic exit by two chemical inhibitors of the APC/C. Nature, 2014, 514(7524): 646-649

[11] NiK, HongL. Current Progress and Perspectives of CDC20 in Female Reproductive Cancers. Curr Mol Med, 2023, 23(3): 193-199

[12] WuF, SunY, ChenJ, et al.. The Oncogenic Role of APC/C Activator Protein Cdc20 by an Integrated Pan-Cancer Analysis in Human Tumors. Front Oncol, 2021, 11: 721797

[13] WangLX, ZhangJF, WanLX, et al.. Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol Ther, 2015, 151: 141-151

[14] LoveMI, HuberW, AndersS. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol, 2014, 15(12): 550

[15] LiJ, GaoJZ, DuJL, et al.. Increased CDC20 expression is associated with development and progression of hepatocellular carcinoma. Int J Oncol, 2014, 45(4): 1547-1555

[16] ZhangY, LiJ, YiK, et al.. Elevated signature of a gene module coexpressed with CDC20 marks genomic instability in glioma. Proc Natl Acad Sci USA, 2019, 116(14): 6975-6984

[17] GayyedMF, El-MaqsoudNM, TawfiekER, et al.. A comprehensive analysis of CDC20 overexpression in common malignant tumors from multiple organs: its correlation with tumor grade and stage. Tumor Biol, 2016, 37(1): 749-762

[18] KarraH, RepoH, AhonenI, et al.. Cdc20 and securin overexpression predict short-term breast cancer survival. Br J Cancer, 2014, 110(12): 2905-2913

[19] ShiR, SunQ, SunJ, et al.. Cell division cycle 20 overexpression predicts poor prognosis for patients with lung adenocarcinoma. Tumor Biol, 2017, 39(3): 1010428317692233

[20] ChangDZ, MaY, JiB, et al.. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol, 2012, 5: 15

[21] ChoiJW, KimY, LeeJH, et al.. High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer. Virchows Arch, 2013, 463(5): 681-687

[22] WuWJ, HuKS, WangDS, et al.. CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer. J Transl Med, 2013, 11: 142

[23] KimY, ChoiJW, LeeJH, et al.. MAD2 and CDC20 are upregulated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the uterine cervix. Int J Gynecol Pathol, 2014, 33(5): 517-523

[24] MouraIMB, DelgadoML, SilvaPMA, et al.. High CDC20 expression is associated with poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med, 2014, 43(3): 225-231

[25] MaoY, LiK, LuL, et al.. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy. Cancer Biomark, 2016, 16(3): 351-358

[26] WuF, WangM, ZhongT, et al.. Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer. Exp Hematol Oncol, 2023, 12(1): 67

[27] DingY, ZhangC, HeL, et al.. Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. Bioengineered, 2021, 12(2): 10791-10798

[28] LubS, MaesA, MaesK, et al.. Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. Oncotarget, 2016, 7(4): 4062-4076

[29] SongC, LoweVJ, LeeS. Inhibition of Cdc20 suppresses the metastasis in triple negative breast cancer (TNBC). Breast Cancer, 2021, 28(5): 1073-1086

[30] GaoY, GuoC, FuS, et al.. Downregulation of CDC20 suppressed cell proliferation, induced apoptosis, triggered cell cycle arrest in osteosarcoma cells, and enhanced chemosensitivity to cisplatin. Neoplasma, 2021, 68(2): 382-390

[31] GaoY, ZhangB, WangY, et al.. Cdc20 inhibitor apcin inhibits the growth and invasion of osteosarcoma cells. Oncol Rep, 2018, 40(2): 841-848

[32] HarperJW, AdamiGR, WeiN, et al.. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 1993, 75(4): 805-816

[33] MalumbresM, BarbacidM. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer, 2001, 1(3): 222-231

[34] KuangY, KangJ, LiH, et al.. Multiple functions of p21 in cancer radiotherapy. J Cancer Res Clin Oncol, 2021, 147(4): 987-1006

[35] MalumbresM, BarbacidM. Mammalian cyclin-dependent kinases. Trends Biochem Sci, 2005, 30(11): 630-641

[36] ZhangS, YuC, YangX, et al.. N-myc downstream-regulated gene 1 inhibits the proliferation of colorectal cancer through emulative antagonizing NEDD4-mediated ubiquitylation of p21. J Exp Clin Cancer Res, 2019, 38(1): 490

[37] KangCM, BaiHL, LiXH, et al.. The binding of lncRNA RP11-732M18.3 with 14-3-3 β/α accelerates p21 degradation and promotes glioma growth. EBioMedicine, 2019, 45: 58-69

[38] XuX, GuJ, DingX, et al.. LINC00978 promotes the progression of hepatocellular carcinoma by regulating EZH2-mediated silencing of p21 and E-cadherin expression. Cell Death Dis, 2019, 10(10): 752

[39] ChipukJE, MoldoveanuT, LlambiF, et al.. The BCL-2 family reunion. Mol Cell, 2010, 37(3): 299-310

[40] TaitSW, GreenDR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol, 2010, 11(9): 621-632

[41] SunQ, LesperanceJ, WetterstenH, et al.. Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis. J Clin Invest, 2018, 128(1): 531-544

[42] KnickelbeinK, TongJ, ChenD, et al.. Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene, 2018, 37(33): 4599-4610

[43] KaverinaNV, KadagidzeZG, BorovjaginAV, et al.. Tamoxifen overrides autophagy inhibition in Beclin-1-deficient glioma cells and their resistance to adenovirus-mediated oncolysis via upregulation of PUMA and BAX. Oncogene, 2018, 37(46): 6069-6082